Abvc Biopharma (ABVC) Operating Expenses (2010 - 2026)

Abvc Biopharma (ABVC) has reported Operating Expenses for 16 consecutive years, with $779526.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Expenses fell 66.03% year-over-year to $779526.0; the trailing twelve-month figure through Jun 2026 stood at $6.5 million (up 48.55% YoY), and the FY2025 full-year result was $7.2 million, up 37.15% from the prior year.
• Operating Expenses retreated to $779526.0 in Q2 2026 per ABVC's latest filing, from $1.6 million in the prior quarter.
• Across five years, Operating Expenses topped out at $6.2 million in Q1 2022 and bottomed at $374794.0 in Q4 2023.
• Historically, Operating Expenses has averaged $2.1 million across 5 years, with a median of $2.1 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Operating Expenses soared 312.14% in 2022, then plunged 89.16% in 2023.
• Over 5 years, Operating Expenses stood at $3.5 million in 2022, then slumped by 89.16% to $374794.0 in 2023, then jumped by 88.51% to $706530.0 in 2024, then jumped by 211.23% to $2.2 million in 2025, then plunged by 64.55% to $779526.0 in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $779526.0, $1.6 million, and $2.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.